FLT3 and acute myeloid leukemia: In the international CALGB 10603/RATIFY trial, the addition of the oral multi-targeted small molecule FLT3 inhibitor midostaurin to intensive induction and consolidation chemotherapy, followed by a 1-year midostaurin maintenance therapy, improved overall survival of patients 18 to 59 years of age with newly diagnosed FLT3-mutated AML [17].